|
業務類別
|
Biotechnology |
|
業務概覽
|
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325,which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
| 公司地址
| 500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701 |
| 電話號碼
| +1 512 900-4690 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.shattucklabs.com |
| 員工數量
| 44 |
| Dr. Abhinav A. Shukla, PhD |
Chief Technical Officer |
-- |
21/05/2025 |
| Mr. Andrew R. Neill |
Chief Financial Officer and Principal Accounting Officer |
美元 458.00K |
05/03/2026 |
| Dr. Arundathy Nirmalini Pandite, MB.Ch.B. |
Chief Medical Officer |
美元 498.00K |
21/05/2025 |
| Dr. Stephen Stout, PhD |
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer |
-- |
21/05/2025 |
| Ms. Casi DeYoung |
Chief Business Officer |
-- |
21/05/2025 |
| Dr. Taylor H. Schreiber, M.D.,PhD |
Chief Executive Officer and Director |
美元 560.00K |
05/03/2026 |
|
|
| Dr. Neil Gibson,PhD |
Independent Director |
05/03/2026 |
| Dr. Clay B. Siegall,PhD |
Independent Director |
05/03/2026 |
| Dr. Daniel G. Baker, PhD |
Independent Director |
05/03/2026 |
| Ms. Helen M. Boudreau, M.B.A. |
Independent Director |
05/03/2026 |
| Dr. Taylor H. Schreiber, M.D.,PhD |
Chief Executive Officer and Director |
05/03/2026 |
| Dr. George S. Golumbeski, PhD |
Chairman of the Board |
05/03/2026 |
| Dr. Mona Ashiya, PhD |
Director |
05/03/2026 |
|
|
|
|
